In this study, we compared the clinical benefit of montelukast versus inhaled fluticasone propionate both clinically, on PEFR, and on some inflammatory mediators as absolute eosinophilic count (AEC), IgE, in addition to leukotrienes in urine in children with chronic asthma. Our study included 80 children with age ranging from 6 to 12 years complaining of chronic asthma for at least one year. The studied children (80) are classified into two groups, group (A)comprises 40 patients given montelukast (5mg) once daily at bed time for at least 12 weeks and group( B) comprises 40 patients receiving inhaled fluticasone (100mcg/) twice daily for at least 12 weeks also. We evaluated the effect of both drugs by comparing history and physical examination, peak expiratory flow rate, complete blood count, total IgE level, and leukotrienes in urine before and after treatment in both groups. Both inhaled fluticasone and montelukast groups showed significant improvement in the various parameters of asthma as regarded the mean number of puffs of B2 agonist, PEFR, AEC and IgE level with no significant difference in the degree of control of both groups. Both montelukast and inhaled fluticasone showed significant decrease in the urinary leukotriene there were statistical significant difference between the two groups after treatment.